AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AMPLIA THERAPEUTICS LTD

0.105

-0.005-4.55%

Volume:702.70K

Turnover:77.23K

Market Cap:53.87M

PE:-6.40

High:0.110

Open:0.110

Low:0.105

Close:0.110

52wk High:0.275

52wk Low:0.100

Shares:513.07M

Float Shares:351.32M

Volume Ratio:3.83

T/O Rate:0.20%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.016

EPS(LYR):-0.016

ROE:-25.48%

ROA:-16.29%

PB:1.36

PE(LYR):-6.40

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Amplia Therapeutics, ANZGOG Finalize Protocol for Phase Two Ovarian Cancer Trial; Shares Up 4%

MT Newswires Live

Amplia Therapeutics Ltd-Amplia and Anzgog Finalise Protocol for Ovarian Cancer Trial

THOMSON REUTERS

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Simply Wall St.

Amplia Therapeutics Signs Trial Collaboration with Lilly for Narmafotinib-Olomorasib NSCLC Study

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/ATX.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ATX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATX.AU\",,,,,undefined,":{"symbol":"ATX.AU","market":"AU","secType":"STK","nameCN":"AMPLIA THERAPEUTICS LTD","latestPrice":0.105,"timestamp":1791431407258,"preClose":0.11,"halted":0,"volume":702703,"delay":0,"changeRate":-0.0454545454545455,"nameEN":"AMPLIA THERAPEUTICS LTD","floatShares":351321835,"shares":513071629,"eps":-0.0164,"marketStatus":"Trading","change":-0.005,"latestTime":"10-08 14:53:41 AEDT","open":0.11,"high":0.11,"low":0.105,"amount":77229,"amplitude":0.045455,"askPrice":0.11,"askSize":179454,"bidPrice":0.105,"bidSize":673755,"shortable":3,"etf":0,"ttmEps":-0.0164,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791435600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.11,"openAndCloseTimeList":[[1791414000000,1791435600000]],"volumeRatio":3.830537,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ATX.AU","preClose":0.11,"auctionPrice":0.11,"auctionVolume":9500,"auctionTime":1791413945125,"referenceTime":1791369003092,"auction":1,"marketStatus":"盘前竞价","timestamp":1791413945125}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATX.AU\",,,,,undefined,":{"symbol":"ATX.AU","floatShares":351321835,"roa":"-16.29%","roe":"-25.48%","lyrEps":-0.0164,"volumeRatio":3.830537,"shares":513071629,"dividePrice":0,"high":0.11,"amplitude":0.045455,"preClose":0.11,"low":0.105,"week52Low":0.1,"pbRate":"1.36","psRate":"11.24","week52High":0.275,"institutionHeld":0,"latestPrice":0.105,"committee":0.579343,"eps":-0.0164,"divideRate":0,"volume":702703,"delay":0,"ttmEps":-0.0164,"open":0.11,"prevYearClose":0.15,"prevWeekClose":0.11,"prevMonthClose":0.115,"prevQuarterClose":0.115,"fiveDayClose":0.115,"twentyDayClose":0.12,"sixtyDayClose":0.145,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATX.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-04-18","symbol":"ATX.AU","defaultRemindTime":1713398400000,"type":"split","dateTimestamp":1713362400000,"forFactor":971896,"toFactor":1000000,"ratio":0.971896}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATX.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667697967","title":"Amplia Therapeutics, ANZGOG Finalize Protocol for Phase Two Ovarian Cancer Trial; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667697967","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667697967?lang=en_us&edition=fundamental","pubTime":"2026-09-15 09:30","pubTimestamp":1789435858,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  and the Australia New Zealand Gynaecological Oncology Group  have finalized the clinical trial protocol for the PRROSE phase two study, clearing a key milestone ahead of the trial's planned commencement, according to a Tuesday filing with the Australian bourse.The trial will evaluate the company's focal adhesion kinase inhibitor narmafotinib in combination with standard chemotherapy in women with high-grade serous ovarian cancer whose tumors show a poor response to chemotherapy before interval debulking surgery, per the filing.The study is expected to enroll around 26 patients at selected sites across Australia and New Zealand, with ethics and site approvals to be secured before patient recruitment begins by the end of the year, the filing added.The company's shares rose 4% in recent Tuesday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","LENZ","BK4007","BK7067","ATX.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667699346","title":"Amplia Therapeutics Ltd-Amplia and Anzgog Finalise Protocol for Ovarian Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667699346","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667699346?lang=en_us&edition=fundamental","pubTime":"2026-09-15 06:21","pubTimestamp":1789424508,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUE7MCVV5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664817028","title":"Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2664817028","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664817028?lang=en_us&edition=fundamental","pubTime":"2026-09-01 05:24","pubTimestamp":1788211494,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-atx/amplia-therapeutics-shares/news/companies-like-amplia-therapeutics-asxatx-are-in-a-position-3","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-atx/amplia-therapeutics-shares/news/companies-like-amplia-therapeutics-asxatx-are-in-a-position-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656567235","title":"Amplia Therapeutics Signs Trial Collaboration with Lilly for Narmafotinib-Olomorasib NSCLC Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2656567235","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656567235?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:45","pubTimestamp":1785847551,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics signs trial collaboration with Lilly for narmafotinib-olomorasib NSCLC studyAmplia entered a clinical trial collaboration and supply agreement with Eli Lilly to test narmafotinib w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL4rKcYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014021.USD","ATX.AU","SG9999014039.USD","BCDF","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","NDAQ","BK4112","BK4585","SG9999014013.SGD","BK4588","BK7067","LU0314104364.USD","LU2210150020.SGD","LU2095319765.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":10,"pageCount":1,"totalSize":37,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ATX.AU\",params:#limit:6,delay:true,,,undefined,":[]}}